Evidence map›Paper›PMID 32860552›Full record

ArticlePituitary2020

Treatment of sellar metastases with gamma knife radiosurgery in patients with advanced cancer.

Carolina Benjamin, Kimberly Ashayeri, John G Golfinos, Dimitris G Placantonakis, Joshua Silverman, Douglas Kondziolka

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Pituitary, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Carolina BenjaminDepartment of Neurosurgery, University of Miami, Lois Pope Life Center, 1095 NE 14th Sreet 2nd Floor, Miami, FL, 33136, USA. carolina.benjamin@med.miami.edu.ORCID http://orcid.org/0000-0001-8134-7943
Kimberly AshayeriDepartment of Neurosurgery, NYU Langone Medical Center, New York, NY, USA.
John G GolfinosDepartment of Neurosurgery, NYU Langone Medical Center, New York, NY, USA.
Dimitris G PlacantonakisDepartment of Neurosurgery, NYU Langone Medical Center, New York, NY, USA.
Joshua SilvermanDepartment of Radiation Oncology, NYU Langone Medical Center, New York, NY, USA.
Douglas KondziolkaDepartment of Neurosurgery, NYU Langone Medical Center, New York, NY, USA.
NYU Langone Health · USUniversity of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMetastases should be considered in a patient with a cancer history and a sellar/suprasellar lesion, as this diagnosis can change the management strategy in such patients. Once the diagnosis is established, stereotactic radiosurgery (SRS) can be a safe and effective approach for these patients.

methodsThis case series describes five patients with pituitary metastases managed with GKRS at a single institution, taken from our prospective registry. All patients had SRS using the Gamma Knife Perfexion or Icon (Elekta), according to our standard institutional protocol. The optic nerves and chiasm were contoured, and the plan was adjusted to restrict dose to the optic apparatus as necessary. The tumor margin doses delivered were 11 Gy, 12 Gy, 14 Gy, 18 Gy (3 sessions of 6 Gy), and 12 Gy at the 50% isodose line.

resultsIn this series, all sellar metastases were treated successfully with good radiographic and clinical response. The histology of the tumors included endometrial, gastrointestinal, and lung adenocarcinomas. Typically, histology is taken into consideration when choosing the treatment dose, along with size and location. In these patients, however, the dose used for the sellar metastases was chosen primarily for visual safety. This was typically lower than the dose for brain metastases in other locations.

conclusionSRS provides an alternative treatment approach for sellar/suprasellar metastases with excellent local control, symptom improvement and maintenance of systemic therapy as desired. As such, CNS failure is rarely the proximate cause of demise in pituitary metastases provided that endocrinopathies are recognized and managed appropriately.

Indexed as

AgedAged, 80 and overBrain NeoplasmsFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPituitary NeoplasmsRadiosurgeryEndoscopic endonasal approachGamma knife radiosurgeryMetastatic cancerPituitary adenomaSellar metastasesStereotactic radiosurgeryTranssphenoidal approach

Identifiers

PMID32860552
OpenAlexW3082551486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.